Ming Kong has deep experience guiding companies in Greater China through their most critical milestones, from pre-IPO financing through listing and beyond. He acts as the lead drafting counsel representing industry-leading companies in connection with a wide variety of capital markets transactions, including some of the most high-profile and high-value deals in the market.

Ming also advises corporate clients, investment banks and private equity funds on various structurally complex financing transactions and general corporate matters.

Ming earned his juris doctor degree from the University of Michigan Law School and his bachelor of laws degree from Renmin University of China. The representative biotech and healthcare IPO prospectuses Ming drafted include Harbour Biopharma, I-Mab, Everest Medicines, JD Health, Medlive Technology and Tran scenta.